| dbo:abstract
|
- برونثالول وهو أحد حاصرات المستقبل بيتا الودي المبكرة والتي درست سريريا. لم يستخدم لاحقا بسبب تأثيره المسرطن في الفئران، ويعتقد أن السبب يعود لتكوين مركبات ناتجة عن . (ar)
- Le pronéthalol était un des premiers candidats de la famille des bêta-bloquants, synthétisé en 1960[réf. souhaitée]. Il n'a cependant jamais été utilisé en médecine humaine dû à sa toxicité cardiaque sur les modèles murins, qui est dû à la formation d'époxide de naphtalène lors de la métabolisation du pronéthalol. (fr)
- Pronethalol (also known as nethalide or compound 38,174; trade name Alderlin) was an early non-selective beta blocker clinical candidate. It was the first beta blocker to be developed by James Black and associates at Imperial Chemical Industries, and the first to enter clinical use, in November 1963. However, it was never used widely due to carcinogenicity in mice, which was thought to result from formation of a carcinogenic naphthalene epoxide metabolite, and was superseded by propranolol from 1965 onward. (en)
- Il pronetalolo è un principio attivo beta-bloccante non selettivo. Fu il primo farmaco di questa categoria ad essere scoperto ed utilizzato, uso che fu presto abbandonato a causa dell'elevata tossicità del composto dovuta all'accumulo di metaboliti del sistema naftalenico a livello epatico, questi comportano danni agli epatociti per intercalazione nel DNA. Sulla base della struttura del pronetalolo è stata in seguito sintetizzata la molecola di propranololo, derivato arilossipropanolamminico più potente e a minore tossicità. (it)
|
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:fdaUniiCode
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 2252 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:chirality
| |
| dbp:h
| |
| dbp:iupacName
| |
| dbp:legalStatus
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- برونثالول وهو أحد حاصرات المستقبل بيتا الودي المبكرة والتي درست سريريا. لم يستخدم لاحقا بسبب تأثيره المسرطن في الفئران، ويعتقد أن السبب يعود لتكوين مركبات ناتجة عن . (ar)
- Le pronéthalol était un des premiers candidats de la famille des bêta-bloquants, synthétisé en 1960[réf. souhaitée]. Il n'a cependant jamais été utilisé en médecine humaine dû à sa toxicité cardiaque sur les modèles murins, qui est dû à la formation d'époxide de naphtalène lors de la métabolisation du pronéthalol. (fr)
- Pronethalol (also known as nethalide or compound 38,174; trade name Alderlin) was an early non-selective beta blocker clinical candidate. It was the first beta blocker to be developed by James Black and associates at Imperial Chemical Industries, and the first to enter clinical use, in November 1963. However, it was never used widely due to carcinogenicity in mice, which was thought to result from formation of a carcinogenic naphthalene epoxide metabolite, and was superseded by propranolol from 1965 onward. (en)
- Il pronetalolo è un principio attivo beta-bloccante non selettivo. Fu il primo farmaco di questa categoria ad essere scoperto ed utilizzato, uso che fu presto abbandonato a causa dell'elevata tossicità del composto dovuta all'accumulo di metaboliti del sistema naftalenico a livello epatico, questi comportano danni agli epatociti per intercalazione nel DNA. Sulla base della struttura del pronetalolo è stata in seguito sintetizzata la molecola di propranololo, derivato arilossipropanolamminico più potente e a minore tossicità. (it)
|
| rdfs:label
|
- برونثالول (ar)
- Pronetalolo (it)
- Pronéthalol (fr)
- Pronethalol (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
